
Emanual Maverakis
Director · University of California Davis Health
Credentials: · · · · ·
History
- 2009–2010
Micrographic Surgery and Dermatologic Oncology
- 2007–2009
Howard Hughes Medical Institute Fellow


- 1999–2003

Research
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy · 2021 · 2,291 citations
Nature Medicine · 2019 · 752 citations
Journal of Investigative Dermatology · 2019 · 406 citations
- SL
39 papers · 28 as a resident

30 papers

19 papers · 3 as a resident
- AT
18 papers · 8 as a resident

17 papers

16 papers · 3 as a resident
- FP
16 papers · 15 as a resident

16 papers · 3 as a fellow
Grants
- 2002–2031
Cancer Center Support Grant P30
National Cancer Institute · P30
Project lead · $158.9K · University of California at Davis
- 2023–2026
HIV Reservoir and Gene Modified Cell Dynamics Following Autologous Stem Cell Transplantation
National Institute of Allergy and Infectious Diseases · R01
PI · $2.4M · University of California, San Francisco
- 2021–2026
Mentoring Translational Scientists in Clinical Trial Immune Monitoring
National Institute of Arthritis and Musculoskeletal and Skin Diseases · K24
Contact PI · $938.6K · University of California at Davis
- 2022–2024
Stratedigm S100EON High-Parameter Flow Cytometer to Support Multi-Institutional Research Programs
NIH Office of the Director · S10
Contact PI · $599.8K · University of California at Davis
Clinical trials
- 2022–2026
The Effects of Dietary Supplementation on Serum Protein Glycosylation
Principal investigator · Recruiting · Phase 1
University of California, Davis
- 2022–2024
Ascending Glycan Dietary Supplementation in Healthy Adults
Principal investigator · Terminated · Phase 1
University of California, Davis
- 2017–2023
Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
Principal investigator · Withdrawn · Phase 3
University of California, Davis
- 2016–2019
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
Principal investigator · Withdrawn · Phase 1, Phase 2
University of California, Davis


